Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

211 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Sildenafil citrate therapy for pulmonary arterial hypertension.
Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Galiè N, et al. Among authors: barst rj. N Engl J Med. 2005 Nov 17;353(20):2148-57. doi: 10.1056/NEJMoa050010. N Engl J Med. 2005. PMID: 16291984 Clinical Trial.
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.
Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT; walk-PHaSST Investigators and Patients. Machado RF, et al. Among authors: barst rj. Blood. 2011 Jul 28;118(4):855-64. doi: 10.1182/blood-2010-09-306167. Epub 2011 Apr 28. Blood. 2011. PMID: 21527519 Free PMC article. Clinical Trial.
STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
Langleben D, Brock T, Dixon R, Barst R; STRIDE-1 study group. Langleben D, et al. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S80-4. doi: 10.1097/01.fjc.0000166207.74178.d0. J Cardiovasc Pharmacol. 2004. PMID: 15838366 Clinical Trial.
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L. Galiè N, et al. J Am Coll Cardiol. 2003 Apr 16;41(8):1380-6. doi: 10.1016/s0735-1097(03)00121-9. J Am Coll Cardiol. 2003. PMID: 12706935 Clinical Trial.
[Guidelines on diagnosis and treatment of pulmonary arterial hypertension].
Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G; Grupo de Trabajo sobre el diagnóstico y tratamiento de la Hipertensión Arterial Pulmonar de la Sociedad Europea de Cardiología. Galiè N, et al. Rev Esp Cardiol. 2005 May;58(5):523-66. doi: 10.1157/13074846. Rev Esp Cardiol. 2005. PMID: 15899198 Spanish. No abstract available.
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, Gómez-Sánchez MA, Grimminger F, Grünig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA. Hoeper MM, et al. Among authors: barst rj. Circulation. 2013 Mar 12;127(10):1128-38. doi: 10.1161/CIRCULATIONAHA.112.000765. Epub 2013 Feb 12. Circulation. 2013. PMID: 23403476 Clinical Trial.
211 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page